| First Author | Vierboom MP | Year | 1997 |
| Journal | J Exp Med | Volume | 186 |
| Issue | 5 | Pages | 695-704 |
| PubMed ID | 9271585 | Mgi Jnum | J:42596 |
| Mgi Id | MGI:1096021 | Doi | 10.1084/jem.186.5.695 |
| Citation | Vierboom MP, et al. (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186(5):695-704 |
| abstractText | The tumor suppressor protein p53 is overexpressed in close to 50% of all human malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing a murine wild-type p53 peptide, presented by the major histocompatibility complex class I molecule H-2Kb, were generated by immunizing p53 gene deficient (p53 -/-) C57BL/6 mice with syngeneic p53-overexpressing tumor cells. Adoptive transfer of these CTLs into tumor-bearing p53 +/+ nude mice caused complete and permanent tumor eradication. Importantly, this occurred in the absence of any demonstrable damage to normal tissue. When transferred into p53 +/+ immunocompetent C57BL/6 mice, the CTLs persisted for weeks in the absence of immunopathology and were capable of preventing tumor outgrowth. Wild-type p53-specific CTLs can apparently discriminate between p53-overexpressing tumor cells and normal tissue, indicating that widely expressed autologous molecules such as p53 can serve as a target for CTL-mediated immunotherapy of tumors. |
